MCG IS1
... you, for example which chemotherapy drugs or surgery would be most suitable. It will also give better information about your risk of developing cancer in the future. What are the possible results of BRCA1/BRCA2 testing and what implications do these results have for me and my family? Testing can rev ...
... you, for example which chemotherapy drugs or surgery would be most suitable. It will also give better information about your risk of developing cancer in the future. What are the possible results of BRCA1/BRCA2 testing and what implications do these results have for me and my family? Testing can rev ...
PREDICT Letter of Med Necessity
... PREDICT94 includes comprehensive variant analysis of 94 genes, including: BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS1 and PMS2. These genes contain well-described variation, and links between these variants and predisposition for certain cancers (including hereditary breast/ovarian cancer, Lynch syndrome, ...
... PREDICT94 includes comprehensive variant analysis of 94 genes, including: BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS1 and PMS2. These genes contain well-described variation, and links between these variants and predisposition for certain cancers (including hereditary breast/ovarian cancer, Lynch syndrome, ...
First genetic factor in prostate cancer prognosis identified
... that suppresses tumours and that protects DNA), 18 patients with mutations in BRCA1 (a gene whose function is similar to BRCA2) and 1,940 patients in which the presence of mutations in bo ...
... that suppresses tumours and that protects DNA), 18 patients with mutations in BRCA1 (a gene whose function is similar to BRCA2) and 1,940 patients in which the presence of mutations in bo ...
A phase III randomized trial of niraparib versus physician`s
... breast or ovarian cancer is 15%, and in patients without a family history of breast cancer the prevalence is reduced to 5%. However data regarding the impact of BRCA mutational status on treatment of breast cancer are currently inconclusive and thus these genes do not currently affect the decision m ...
... breast or ovarian cancer is 15%, and in patients without a family history of breast cancer the prevalence is reduced to 5%. However data regarding the impact of BRCA mutational status on treatment of breast cancer are currently inconclusive and thus these genes do not currently affect the decision m ...
Whole-exome sequencing to study predisposition for breast cancer
... pairs of identical twins and 1075 pairs of non‐identical twins) ...
... pairs of identical twins and 1075 pairs of non‐identical twins) ...
Genetic testing for BRCA1 and BRCA2 (breast and ovarian cancers)
... 4. Other features, such as the occurrence of several cancers in one individual. 5. An unusual situation such as breast cancer in a male. People from certain ethnic backgrounds may also be at higher cancer risk. Looking at this in relation to you and your own family we believe it to be possible that ...
... 4. Other features, such as the occurrence of several cancers in one individual. 5. An unusual situation such as breast cancer in a male. People from certain ethnic backgrounds may also be at higher cancer risk. Looking at this in relation to you and your own family we believe it to be possible that ...
Hereditary Breast and Ovarian Cancer Syndrome Factsheet
... Other genes that contribute to breast and ovarian cancer There are other hereditary cancer syndromes that increase the risk for breast cancer, such as Cowden syndrome and LiFraumeni syndrome. The presentation of these syndromes in a family may overlap with that of HBOC, but can sometimes be distingu ...
... Other genes that contribute to breast and ovarian cancer There are other hereditary cancer syndromes that increase the risk for breast cancer, such as Cowden syndrome and LiFraumeni syndrome. The presentation of these syndromes in a family may overlap with that of HBOC, but can sometimes be distingu ...
Topic: Hereditary breast/ovarian cancer
... - Multiple cases of breast and/or ovarian cancer in family, especially o in closely related relatives o in more than one generation, and o when breast cancer is diagnosed before age 50 - A family member with breast cancer diagnosed before age 35; - A family member with both breast and ovarian cancer ...
... - Multiple cases of breast and/or ovarian cancer in family, especially o in closely related relatives o in more than one generation, and o when breast cancer is diagnosed before age 50 - A family member with breast cancer diagnosed before age 35; - A family member with both breast and ovarian cancer ...
Old and new drugs for hereditary cancers Evgeny N. Imyanitov N.N.
... Evgeny N. Imyanitov N.N. Petrov Institute of Oncology, St.-Petersburg, Russia There is an impressive progress in the development of specific treatments for hereditary cancers. The most common type of familial cancer syndrome, BRCA1/2-related breast/ovarian cancer (BC/OC), is characterized by a prono ...
... Evgeny N. Imyanitov N.N. Petrov Institute of Oncology, St.-Petersburg, Russia There is an impressive progress in the development of specific treatments for hereditary cancers. The most common type of familial cancer syndrome, BRCA1/2-related breast/ovarian cancer (BC/OC), is characterized by a prono ...
examining the attitude towards prophylactic oophorectomy among
... During the past few years, the genes BRCA1 and BRCA2 were identified. Mutations in each is responsible of the syndrome of familial breast and ovarian carcinoma. Among women that carry a mutation like this there is a risk of 56%-80% of developing breast cancer during life-time and 16%-60% risk of dev ...
... During the past few years, the genes BRCA1 and BRCA2 were identified. Mutations in each is responsible of the syndrome of familial breast and ovarian carcinoma. Among women that carry a mutation like this there is a risk of 56%-80% of developing breast cancer during life-time and 16%-60% risk of dev ...
BRCA1 and BRCA2 in Men
... BRCA1 and BRCA2 in Men Everyone has BRCA1 and BRCA2 genes. These genes help repair damage to the DNA within cells. However, some individuals inherit a mutation in one of their BRCA genes, which increases their risk for certain cancers, including breast (female and male), ovarian, pancreatic and pros ...
... BRCA1 and BRCA2 in Men Everyone has BRCA1 and BRCA2 genes. These genes help repair damage to the DNA within cells. However, some individuals inherit a mutation in one of their BRCA genes, which increases their risk for certain cancers, including breast (female and male), ovarian, pancreatic and pros ...
Single site BRACAnalysis Sample LMN
... I am writing to request coverage for genetic testing of a known familial mutation in the [choose one] BRCA1/BRCA2 gene for the above patient. Based on the presence of this mutation in the family, this patient is at significantly increased risk [choose one or insert number if known] (50%/25%/12.5%) t ...
... I am writing to request coverage for genetic testing of a known familial mutation in the [choose one] BRCA1/BRCA2 gene for the above patient. Based on the presence of this mutation in the family, this patient is at significantly increased risk [choose one or insert number if known] (50%/25%/12.5%) t ...
Genetics of Hereditary Breast and Ovarian Cancer
... cancers (such as breast/ovarian/pancreatic cancer) found in the same family. Individuals of Ashkenazi Jewish ancestry are also at greater risk for hereditary breast and ovarian cancer. In addition, emerging data suggest that certain features are overrepresented in hereditary breast and ovarian cance ...
... cancers (such as breast/ovarian/pancreatic cancer) found in the same family. Individuals of Ashkenazi Jewish ancestry are also at greater risk for hereditary breast and ovarian cancer. In addition, emerging data suggest that certain features are overrepresented in hereditary breast and ovarian cance ...
Hereditary Breast and Ovarian Cancer (HBOC)
... What you should know about Hereditary Breast and Ovarian Cancer (HBOC) Approximately 5-10% of breast cancer is inherited. Most hereditary breast cancers are caused by mutations in the BRCA1 and BRCA2 genes, but there are other genes that can cause inherited breast cancers. ...
... What you should know about Hereditary Breast and Ovarian Cancer (HBOC) Approximately 5-10% of breast cancer is inherited. Most hereditary breast cancers are caused by mutations in the BRCA1 and BRCA2 genes, but there are other genes that can cause inherited breast cancers. ...
BRCA2
BRCA2 and BRCA2 (/ˌbrækəˈtuː/) are a human gene and its protein product, respectively. The official symbol (BRCA2, italic for the gene, nonitalic for the protein) and the official name (breast cancer 2, early onset) are maintained by the HGNC. Orthologs, styled Brca2 and Brca2, are common in other mammal species. BRCA2 is a human tumor suppressor gene (specifically, a caretaker gene), found in all humans; its protein, also called by the synonym breast cancer type 2 susceptibility protein, is responsible for repairing DNA.BRCA2 and BRCA1 are normally expressed in the cells of breast and other tissue, where they help repair damaged DNA or destroy cells if DNA cannot be repaired. They are involved in the repair of chromosomal damage with an important role in the error-free repair of DNA double strand breaks. If BRCA1 or BRCA2 itself is damaged by a BRCA mutation, damaged DNA is not repaired properly, and this increases the risk for breast cancer. Thus, although the terms ""breast cancer susceptibility gene"" and ""breast cancer susceptibility protein"" (used frequently both in and outside the medical literature) sound as if they describe a proto-oncogene or oncogene, BRCA1 and BRCA2 are ""normal""; it is their mutation that is abnormal.The BRCA2 gene is located on the long (q) arm of chromosome 13 at position 12.3 (13q12.3). The human reference BRCA 2 gene contains 28 exons, and the cDNA has 10,254 base pairs coding for a protein of 3418 amino acids.The gene was first cloned by scientists at Myriad Genetics, Endo Recherche, Inc., HSC Research & Development Limited Partnership, and the University of Pennsylvania.Methods to diagnose the likelihood of a patient with mutations in BRCA1 and BRCA2 getting cancer were covered by patents owned or controlled by Myriad Genetics. Myriad's business model of exclusively offering the diagnostic test led from Myriad being a startup in 1994 to being a publicly traded company with 1200 employees and about $500M in annual revenue in 2012; it also led to controversy over high prices and the inability to get second opinions from other diagnostic labs, which in turn led to the landmark Association for Molecular Pathology v. Myriad Genetics lawsuit.